Sangha, R.; Davies, N.M.; Namdar, A.; Chu, M.; Spratlin, J.; Beauchamp, E.; Berthiaume, L.G.; Mackey, J.R.
Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma. Curr. Oncol. 2022, 29, 1939-1946.
https://doi.org/10.3390/curroncol29030158
AMA Style
Sangha R, Davies NM, Namdar A, Chu M, Spratlin J, Beauchamp E, Berthiaume LG, Mackey JR.
Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma. Current Oncology. 2022; 29(3):1939-1946.
https://doi.org/10.3390/curroncol29030158
Chicago/Turabian Style
Sangha, Randeep, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume, and John R. Mackey.
2022. "Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma" Current Oncology 29, no. 3: 1939-1946.
https://doi.org/10.3390/curroncol29030158
APA Style
Sangha, R., Davies, N. M., Namdar, A., Chu, M., Spratlin, J., Beauchamp, E., Berthiaume, L. G., & Mackey, J. R.
(2022). Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma. Current Oncology, 29(3), 1939-1946.
https://doi.org/10.3390/curroncol29030158